Feb. 2 at 10:53 PM
$SGMT Updated Feb 2026 Corp Deck has a couple of interesting changes.
- P2 Combo trial is expected to initiate in 2H 2026 and have 4-5 arms including a monotherapy arm of each agent and a up to 2 combo arms plus a placebo.
- Updates include today's PR on the Ascletis P3 results.
- There is a new emphasis on the selection of one of the licensed innovative forms of resmetirom from TAPI to develop a once-daily FDC tablet for a potential Phase 3 trial.
I'm not sure if it gets enough attention, but the SGMT combo therapy is specifically addressing the F4 patient population. Given that rez has only contingently approved for F2/F3, it would be a huge boost to SGMT if rezdiffra gets denied approval in the F4 population from both a legal and financial perspective.
